Published in J Clin Oncol on January 20, 2005
In search of the perfect comorbidity measure for use with administrative claims data: does it exist? Med Care (2006) 2.53
Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer (2010) 1.12
Lower vitamin-D production from solar ultraviolet-B irradiance may explain some differences in cancer survival rates. J Natl Med Assoc (2006) 1.07
Cancer stage at diagnosis and survival among persons with Social Security Disability Insurance on Medicare. Health Serv Res (2007) 1.04
Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and white Americans. Dermatoendocrinol (2012) 1.03
Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer. J Natl Cancer Inst (2013) 1.02
Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study. J Am Coll Surg (2013) 1.02
Racial differences in survival after surgical treatment for melanoma. Ann Surg Oncol (2011) 0.95
The role of socio-economic status in the decision making on diagnosis and treatment of oesophageal cancer in The Netherlands. Br J Cancer (2006) 0.92
Short- and long-term risk of colorectal adenoma recurrence among whites and blacks. Gastrointest Endosc (2013) 0.92
Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. Onco Targets Ther (2010) 0.90
Racial differences in stage at diagnosis and survival from epithelial ovarian cancer: a fundamental cause of disease approach. Soc Sci Med (2010) 0.89
Racial disparities in esophageal cancer outcomes. Ann Surg Oncol (2012) 0.83
The role of unconscious bias in surgical safety and outcomes. Surg Clin North Am (2011) 0.83
Disparities in oncologic surgery. World J Surg (2008) 0.78
Racial disparities in surgical resection and survival among elderly patients with poor prognosis cancer. J Am Coll Surg (2012) 0.78
Gastric adenocarcinoma: clinicopathologic differences among Hispanics and non-Hispanic whites. A single Institution's experience over 14 years. Ann Gastroenterol (2016) 0.75
The effect of individual and neighborhood socioeconomic status on esophageal cancer survival in working-age patients in Taiwan. Medicine (Baltimore) (2016) 0.75
Diminishing disparities: starting in our own backyards. Ann Surg Oncol (2007) 0.75
Making sense of racial disparities in gastrointestinal cancer mortality. Dig Dis Sci (2012) 0.75
Malignant Melanoma in African-Americans: A Population-Based Clinical Outcomes Study Involving 1106 African-American Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1988-2011). Medicine (Baltimore) (2017) 0.75
Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study. Drug Des Devel Ther (2016) 0.75
The impact of gender, race, socioeconomic status, and treatment on outcomes in esophageal cancer: A population-based analysis. J Carcinog (2017) 0.75
Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol (2004) 7.45
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med (2009) 6.46
Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol (2008) 5.61
Under use of necessary care among cancer survivors. Cancer (2004) 5.31
Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet (2004) 4.99
Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol (2003) 4.50
Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol (2009) 4.39
Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) (2006) 4.33
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ (2004) 4.13
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst (2006) 4.01
Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ (2014) 3.90
Physician factors associated with discussions about end-of-life care. Cancer (2010) 3.54
Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation. J Clin Oncol (2011) 3.53
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36
How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff (Millwood) (2010) 3.24
Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst (2006) 3.19
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst (2012) 3.16
Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg (2003) 3.13
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol (2010) 2.97
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA (2010) 2.93
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol (2013) 2.91
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care (2005) 2.75
Views of American oncologists about the purposes of clinical trials. J Natl Cancer Inst (2002) 2.71
American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol (2008) 2.69
Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol (2008) 2.68
Trends in follow-up and preventive care for colorectal cancer survivors. J Gen Intern Med (2008) 2.64
Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol (2014) 2.62
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA (2012) 2.56
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol (2011) 2.52
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol (2005) 2.48
Association of hospital spending intensity with mortality and readmission rates in Ontario hospitals. JAMA (2012) 2.47
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med (2009) 2.36
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst (2006) 2.34
Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. Ann Intern Med (2011) 2.34
Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol (2011) 2.31
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol (2006) 2.29
A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network. Ann Surg (2006) 2.29
Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer (2003) 2.26
Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol (2009) 2.26
The interface between primary and oncology specialty care: treatment through survivorship. J Natl Cancer Inst Monogr (2010) 2.25
Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program. Med Care (2013) 2.22
The effect of race on invasive staging and surgery in non-small-cell lung cancer. J Clin Oncol (2005) 2.21
Patients' experiences with care for lung cancer and colorectal cancer: findings from the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2010) 2.16
Parents' views of cancer-directed therapy for children with no realistic chance for cure. J Clin Oncol (2008) 2.12
Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst (2003) 2.11
End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med (2012) 2.08
Measuring complications of cancer treatment using the SEER-Medicare data. Med Care (2002) 2.05
End-of-life care for older cancer patients in the Veterans Health Administration versus the private sector. Cancer (2010) 2.01
Physician roles in the cancer-related follow-up care of cancer survivors. Fam Med (2013) 2.00
Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol (2012) 2.00
Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol (2012) 1.95
Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.94
Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline concordance. J Natl Cancer Inst (2011) 1.92
The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med (2002) 1.90
Treatment decision making in early-stage breast cancer: should surgeons match patients' desired level of involvement? J Clin Oncol (2002) 1.89
Site of oncologic specialty care for older adolescents in Utah. J Clin Oncol (2007) 1.87
Cancer patients' roles in treatment decisions: do characteristics of the decision influence roles? J Clin Oncol (2010) 1.84
Parent and physician perspectives on quality of care at the end of life in children with cancer. J Clin Oncol (2005) 1.78
Discussions with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med (2009) 1.77
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75
Looking back from death: the value of retrospective studies of end-of-life care. J Clin Oncol (2006) 1.75
Racial and ethnic differences in end-of-life care in fee-for-service Medicare beneficiaries with advanced cancer. J Am Geriatr Soc (2008) 1.74
Hope and prognostic disclosure. J Clin Oncol (2007) 1.73
Breast cancer survivors' perceptions of survivorship care options. J Clin Oncol (2011) 1.72
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst (2011) 1.71
Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst (2005) 1.70
Comparison of prospective and retrospective indicators of the quality of end-of-life cancer care. J Clin Oncol (2008) 1.70
Selecting high priority quality measures for breast cancer quality improvement. Med Care (2008) 1.70
Medical oncologists' perceptions of financial incentives in cancer care. J Clin Oncol (2012) 1.69
Communication about prognosis between parents and physicians of children with cancer: parent preferences and the impact of prognostic information. J Clin Oncol (2006) 1.66
The effect on survival of continuing chemotherapy to near death. BMC Palliat Care (2011) 1.66
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol (2006) 1.64
Health care costs associated with hepatocellular carcinoma: a population-based study. Hepatology (2013) 1.63
Improving the care of children with advanced cancer by using an electronic patient-reported feedback intervention: results from the PediQUEST randomized controlled trial. J Clin Oncol (2014) 1.63